Document Detail

Circulating Interleukin-6 level is a prognostic marker for survival in advanced non-small cell lung cancer patients treated with chemotherapy.
MedLine Citation:
PMID:  23034889     Owner:  NLM     Status:  Publisher    
Lung cancer is the leading cause of cancer death worldwide as well as in Taiwan. Interleukin-6 (IL-6) is a multifunctional cytokine and has been implicated in tumor progression. The present study recruited 245 patients with advanced (Stage 3B/4) non-small cell lung cancer (NSCLC) that had received chemotherapy, to evaluate associations between IL-6 and lung cancer-specific survival. Among these subjects, 112 gave blood samples before and 133 after the start of chemotherapy. Plasma IL-6 was measured using an enzyme linked-immuno-sorbent assay. The 33rd and 66th percentiles of IL-6 concentrations were 2.01 and 25.16 for the 245 patients, and were defined as the cutoff points for dividing the patients into low, intermediate, and high groups. Kaplan-Meier and Cox proportional-hazard models were used to evaluate the relationship between the IL-6 level and survival time. Results after adjusting for age, sex, smoking history, histologic type, and stage of lung cancer revealed a significant relationship. For all patients, the hazard ratio with high IL-6 levels for lung cancer-specific survival was 2.10 (95% confidence interval (CI)= 1.49-2.96) compared with low IL-6 levels. The hazard ratio for patients who were recruited before and after the start of chemotherapy was1.25 (95% CI= 0.73-2.13) and 3.66 (95% CI= 2.18-6.15), respectively. Patients with high circulating IL-6 also responded poorly to chemotherapy. Therefore, a high level of circulating IL-6 was associated with an inferior response and survival outcome in NSCLC patients treated with chemotherapy. © 2012 Wiley Periodicals, Inc.
Chin Hao Chang; Chin Fu Hsiao; Yu Min Yeh; Gee Chen Chang; Ying Huang Tsai; Yuh Min Chen; Ming Shyan Huang; Hui Ling Chen; Yao Jen Li; Pan Chyr Yang; Chien Jen Chen; Chao A Hsiung; Wu Chou Su
Related Documents :
23883669 - Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph node...
11552789 - Holmium:yag laser treatment of recurrent superficial bladder carcinoma: initial clinica...
2244019 - The importance of vocal cord mobility in t2 laryngeal cancer.
18468419 - Is total glossectomy for advanced carcinoma of the tongue justified?
23774619 - Mediastinal lymph-nodes metastasis beyond the lobe-specific: an independent risk factor...
24628269 - Adaptive radiotherapy in lung cancer: dosimetric benefits and clinical outcome.
17652649 - High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
2029409 - Dna as a prognostic marker in advanced high-grade prostatic cancer. a preliminary repor...
15956789 - Comparative study of tolerance between unmodified and high doses of chemically modified...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-4
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 UICC.
No. 35, Xiao-Dong Road, National Cheng Kung University Hospital, Tainan, Taiwan 704, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surgical Instrument Tracking Optimizes Trans-Sphenoidal Endoscopic Treatment of Petrous Apex Cholest...
Next Document:  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treat...